A new cancer vaccine that boosts immune response through B and T cell interaction
Official title: Therapeutic Cancer NanoVaccine Promotes B/CD 4 T Cell Crosstalk for Durable Anticancer Efficacy
Funded at University of Michigan at Ann Arbor · NIH-11026367 · Data updated 2026-11-12
This study is testing a new cancer vaccine that helps your immune system work better by improving how certain immune cells talk to each other, and it's designed for people with different types of cancer who want to see if this vaccine can help them fight their disease more effectively.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | University of Michigan at Ann Arbor NIH-funded |
| Lab location | 1 site (Ann Arbor, United States) |
| Project start | February 5, 2024 |
| Project end | January 31, 2029 |
| Funding year | 2025 |
| Award (this year) | $529,077 |
| NIH project number | 5R01CA285790-02 |
| Project ID | NIH-11026367 on NIH RePORTER |
Who could benefit from this research
✓Could help
Ideal candidates for this research are individuals diagnosed with cancer who are seeking new treatment options and have not responded adequately to existing therapies.
✕Less likely to help
Patients with early-stage cancers that are easily treatable with current standard therapies may not benefit from this research.
What this research studies
This research investigates a novel cancer vaccine designed to enhance the immune response by promoting communication between B cells and CD4 T cells. The approach focuses on improving how B cells present antigens to T cells, which is crucial for a durable anticancer effect. By utilizing a specialized delivery system, the vaccine aims to activate B cell immunity alongside traditional T cell responses, potentially leading to better outcomes for various cancer types. Patients may be involved in trials to assess the vaccine's effectiveness and safety.
Why it matters
Potential benefit: If successful, this research could lead to a more effective cancer vaccine that provides long-lasting immunity against various cancers.
How similar studies have gone: Previous research has shown promising results with similar approaches that enhance immune responses through B cell activation, indicating potential for success in this novel strategy.
Where this research is happening
-
University of Michigan at Ann Arbor
Ann Arbor, United States Active
Researchers
- Principal investigator: Sun, Duxin — University of Michigan at Ann Arbor
- Study coordinator: Sun, Duxin
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page.